Showing results (521-530 of 579) with videos related to
Sort By:
Pageof 58
Blood|February 26, 2025
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AMLJing Lu, Shengli Xue, Ying Wang, et al.Blood Cancer Journal|April 24, 2023
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?Sining Liu, Xinyue Zhang, Haiping Dai, et al.Immunology|July 7, 2022
E3 ubiquitin ligase MID1 ubiquitinates and degrades type-I interferon receptor 2Xiangjie Chen, Qian Zhao, Ying Xu, et al.Blood Advances|January 4, 2018
Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri, et al.Leukemia & Lymphoma|March 13, 2024
Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantationJinjin Zhu, Mimi Xu, Yuhua Ru, et al.Bone Marrow Transplantation|August 20, 2024
Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMTArnon Nagler, Myriam Labopin, Urpu Salmenniemi, et al.Journal of Hematology & Oncology|July 8, 2017
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation studyJian Hou, Jie Jin, Yan Xu, et al.Bone Marrow Transplantation|December 24, 2025
The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutationsIman Abou Dalle, Jacques-Emmanuel Galimard, Xavier Poire, et al.Journal of Hematology & Oncology|September 1, 2024
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trialJing Lu, Huiying Qiu, Ying Wang, et al.Cancer Letters|September 16, 2018
The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in ChinaYu Wang, Hu Chen, Jing Chen, et al.Pageof 58